• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BioCardia Inc. (Amendment)

    2/13/23 4:40:39 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCDA alert in real time by email
    SC 13G/A 1 bcda_13gv5.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

     

    BioCardia, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001
    (Title of Class of Securities)
     
    09060U507
    (CUSIP Number)
     
    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)
    o Rule 13d-1(c)
    o Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 09060U50713G/APage 1 of 7 Pages

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Catalysis Partners, LLC

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (SEE INSTRUCTIONS)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    1,017,719

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    1,017,719

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,017,719

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.1% (See Note 1)

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    PN

     

           

    (1)Based on 20,045,500 outstanding shares of Common Stock (as defined below) as of December 16, 2022, as represented by the Issuer in the Form S-3 filed with the Securities and Exchange Commission ("SEC") on December 19, 2022.

     

     

    CUSIP No. 09060U50713G/APage 2 of 7 Pages

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Francis Capital Management, LLC

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (SEE INSTRUCTIONS)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    California

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    1,017,719

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    1,017,719

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,017,719

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.1% (See Note 2)

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IA, HC,OO

     

           

    (2)See Note (1) Above.

    CUSIP No. 09060U50713G/APage 3 of 7 Pages

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    John Francis

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (SEE INSTRUCTIONS)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    100,000

     

     

    6.

     

    SHARED VOTING POWER

    1,047,719 (See Note 3)

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    100,000

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    1,047,719 (See Note 3)

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,147,719

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.7% (See Note 4)

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IN, HC

     

           

    (3) John Francis owns 100,000 shares individually. He and his wife also own 30,000 shares jointly. John Francis shares voting and dispositive power of the shares.

     

    (4) See Note (1) Above.

     

    CUSIP No. 09060U50713G/APage 4 of 7 Pages

     

    AMENDMENT NO. 2 TO SCHEDULE 13G

     

    Reference is hereby made to the statement on Schedule 13G filed with the Securities and Exchange Commission by the Reporting Persons on June 21, 2021 with respect to the Common Stock of the Issuer and Amendment No. 1 thereto filed on February 14, 2022 (the “Schedule 13G/A“). Terms defined in the Schedule 13G are used herein as so defined.

     

    The following Items of the Schedule 13G are amended and restated to read in their entirety as follows:

     

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (e) [x] Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940

    (g) [x] Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G)

     

    Item 4.Ownership

     

    (i)Catalysis Partners, LLC

     

    (a)Amount beneficially owned: 1,017,719 (See Note 5)

     

    (b)Percent of class: 5.1% (See Note 6)

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 1,017,719 (See Note 5)

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 1,017,719 (See Note 5)

     

    (ii)Francis Capital Management, LLC

     

    (a)Amount beneficially owned: 1,017,719 (See Note 5)

     

    (b)Percent of class: 5.1% (See Note 6)

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 1,017,719 (See Note 5)

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 1,017,719 (See Note 5)

     

    (iii)John Francis

     

    (a)Amount beneficially owned: 1,147,719 (See Note 5)

     

    (b)Percent of class: 5.7% (See Note 6)

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 100,000

     

    (ii)Shared power to vote or to direct the vote: 1,047,719 (See Note 5)

     

    (iii)Sole power to dispose or to direct the disposition of: 100,000

     

    (iv)Shared power to dispose or to direct the disposition of: 1,047,719 (See Note 5)

     

    CUSIP No. 09060U507 13G/A Page 5 of 7 Pages

     

     

    Note 5:

     

    Francis Capital Management, LLC is registered as an investment adviser with the State of California. Francis Capital Management, LLC, which serves as the general partner and investment manager to Catalysis Partners, LLC, (the "Fund"), may be deemed to be the beneficial owner of all shares of Common Stock held by the Fund. Mr. John Francis, as Managing Member of Francis Capital Management, LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Fund.

     

    Note 6:

     

    Based on 20,045,500 outstanding shares of Common Stock as of December 16, 2022 as represented by the Issuer in the Form S-3 filed with the SEC on December 19, 2022.

     

      

     

    Item 10.Certifications:

     

    Each of the Reporting Persons makes the following certification:

     

    By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: February 13, 2023

     

     

     

    CATALYSIS PARTNERS, LLC

    By: Francis Capital Management, LLC, its General Partner

    By: /s/ John Francis

    Name: John Francis

    Title: Managing Member

     

     

    FRANCIS CAPITAL MANAGEMENT, LLC

    By: /s/ John Francis

    Name: John Francis

    Title: Managing Member

     

     

    JOHN FRANCIS

    By: /s/ John Francis

     

     

    CUSIP No. 09060U507 13G/A Page 6 of 7 Pages

     

     

    EXHIBIT A

     

    Joint Filing Agreement Pursuant to Rule 13d-1

     

    This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities Exchange Act of 1934, as amended (the "Act") by and among the parties listed below, each referenced to herein as a "Joint Filer". The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the rules thereunder may be filed on each of his, her or its behalf on Schedule 13G or Schedule 13D, as appropriate, and that said joint filing may thereafter be amended by further joint filings. The Joint Filers state that they each satisfy the requirements for making a joint filing under Rule 13d-1(k).

     

     

    Dated: February 13, 2023
         

    CATALYSIS PARTNERS, LLC

    By: Francis Capital Management, LLC, its General Partner

    By: /s/ John Francis

    Name: John Francis

    Title: Managing Member

     

     

    FRANCIS CAPITAL MANAGEMENT, LLC

    By: /s/ John Francis

    Name: John Francis

    Title: Managing Member

     

     

    JOHN FRANCIS

    By: /s/ John Francis

     

     

     

     

    CUSIP No. 09060U507 13G/A Page 7 of 7 Pages

    Get the next $BCDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCDA

    DatePrice TargetRatingAnalyst
    12/20/2021$9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on BioCardia with a new price target

      HC Wainwright & Co. initiated coverage of BioCardia with a rating of Buy and set a new price target of $9.00

      12/20/21 6:05:04 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia downgraded by Dawson James

      Dawson James downgraded BioCardia from Buy to Neutral

      4/16/21 7:22:02 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BioCardia Inc.

      SC 13G - BioCardia, Inc. (0000925741) (Subject)

      9/6/24 7:45:48 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

      SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

      4/5/24 4:13:08 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

      SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

      2/27/24 4:53:40 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Krasno Richard M bought $24,999 worth of shares (13,123 units at $1.90), increasing direct ownership by 417% to 16,268 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/28/25 6:46:32 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Mcclung David bought $24,999 worth of shares (13,123 units at $1.90), increasing direct ownership by 44% to 43,131 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/25/25 9:38:27 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Facteau Bill bought $24,999 worth of shares (13,123 units at $1.90) (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/25/25 9:37:32 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Financials

    Live finance-specific insights

    See more
    • BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

      SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10199950/ff25def0f6.   Please note that registered participants will receive their dial-in number upon registration. For those who have

      5/9/25 4:28:08 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

      SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT. To access the call today:Participants can register for the conference by navigating to https://dpregister.com/sreg/10194429/fdf5f0e427. Please note that registered participants will receive their dial-in number upon registration. For those who have no

      3/31/25 1:39:56 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years

      Increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE) observed study-wide, despite primary composite efficacy endpoint not reaching statistical significanceStatistically significant improvement in composite outcome measure comprised of survival, MACCE, and quality of life seen in patients suffering from active heart stress (those with elevated NTproBNP and BNP biomarkers) treated with CardiAMP Cell TherapyPatient improvements through two years suggest single dose of CardiAMP therapy offers durable benefits SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for

      3/31/25 8:00:00 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    SEC Filings

    See more
    • BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BioCardia, Inc. (0000925741) (Filer)

      5/6/25 8:00:09 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BioCardia, Inc. (0000925741) (Filer)

      5/1/25 9:00:10 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by BioCardia Inc.

      S-3 - BioCardia, Inc. (0000925741) (Filer)

      4/30/25 5:13:07 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

      SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10199950/ff25def0f6.   Please note that registered participants will receive their dial-in number upon registration. For those who have

      5/9/25 4:28:08 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study

      CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) and Elevated Markers of Cardiac Stress Dr. Amish Raval, Professor of Medicine at the University of Wisconsin School of Medicine and Public Health, to serve as Site Principal Investigator and Co-National Principal Investigator SUNNYVALE, Calif., May 06, 2025 (GLOBE NEWSWIRE) --  BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that University of Wisconsin in Madison, Wisconsin is now enrolling patients with ischemic HFrEF in

      5/6/25 8:00:00 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company's Lead Cell Therapy for Treatment of Heart Failure

      SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the first patient enrolled in the Phase III randomized procedure placebo-controlled double-blind CardiAMP HF II clinical trial of the Company's lead autologous cell therapy program for the treatment of heart failure at BayCare Morton Plant Hospital in Clearwater, Florida. "We are excited to lead enrollment in the CardiAMP HF II trial and be able to offer this cell therapy study to our heart failure patients. This investigational therapy has been shown to enhance micro

      5/1/25 9:00:00 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Krasno Richard M bought $24,999 worth of shares (13,123 units at $1.90), increasing direct ownership by 417% to 16,268 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/28/25 6:46:32 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Mcclung David bought $24,999 worth of shares (13,123 units at $1.90), increasing direct ownership by 44% to 43,131 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/25/25 9:38:27 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Facteau Bill bought $24,999 worth of shares (13,123 units at $1.90) (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/25/25 9:37:32 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care